Literature DB >> 32645241

The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease.

Yu Liu1, Xi Jin1, Hyokyoung G Hong2, Liyuan Xiang1, Qingyao Jiang1, Yucheng Ma1, Zude Chen1, Liang Cheng1, Zhongyu Jian1, Zhitao Wei1, Jianzhong Ai1, Shiqian Qi3, Qun Sun4, Hong Li1, Yi Li5, Kunjie Wang1.   

Abstract

The relationship of gut microbiota and calcium oxalate stone has been limited investigated, especially with no study of gut microbiota and short chain fatty acids (SCFAs) in nephrolithiasis. We provided Sprague Dawley rats of renal calcium oxalate stones with antibiotics and examined the renal crystals deposition. We also performed a case-control study by analyzing 16S rRNA microbial profiling, shotgun metagenomics and SCFAs in 153 fecal samples from non-kidney stone (NS) controls, patients with occasional renal calcium oxalate stones (OS) and patients with recurrent stones (RS). Antibiotics reduced bacterial load in feces and could promote the formation of renal calcium crystals in model rats. In addition, both OS and RS patients exhibited higher fecal microbial diversity than NS controls. Several SCFAs-producing gut bacteria, as well as metabolic pathways associated with SCFAs production, were considerably lower in the gut microbiota among the kidney stone patients compared with the NS controls. Representation of genes involved in oxalate degradation showed no significance difference among groups. However, fecal acetic acid concentration was the highest in RS patients with high level of urinary oxalate, which was positively correlated with genes involvement in oxalate synthesis. Administration of SCFAs reduced renal crystals. These results shed new light on bacteria and SCFAs, which may promote the development of treatment strategy in nephrolithiasis.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  16s Rrna; renal calcium oxalate stones; sgut microbiota; short chain fatty acids; shotgun metagenomics

Year:  2020        PMID: 32645241     DOI: 10.1096/fj.202000786R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  Renal Sensing of Bacterial Metabolites in the Gut-kidney Axis.

Authors:  Orestes Foresto-Neto; Bruno Ghirotto; Niels Olsen Saraiva Câmara
Journal:  Kidney360       Date:  2021-07-02

Review 2.  Mechanisms of the intestinal and urinary microbiome in kidney stone disease.

Authors:  Aaron W Miller; Kristina L Penniston; Kate Fitzpatrick; José Agudelo; Gregory Tasian; Dirk Lange
Journal:  Nat Rev Urol       Date:  2022-09-20       Impact factor: 16.430

Review 3.  Domestic Environment and Gut Microbiota: Lessons from Pet Dogs.

Authors:  Juan Hernandez; Soufien Rhimi; Aicha Kriaa; Vincent Mariaule; Houda Boudaya; Amandine Drut; Amin Jablaoui; Héla Mkaouar; Amel Saidi; Vincent Biourge; Mohamed Ali Borgi; Moez Rhimi; Emmanuelle Maguin
Journal:  Microorganisms       Date:  2022-04-30

4.  Association of Gut Microbiota and Biochemical Features in a Chinese Population With Renal Uric Acid Stone.

Authors:  Cheng Cao; Bo Fan; Jin Zhu; Na Zhu; Jing-Yuan Cao; Dong-Rong Yang
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

5.  Identifying Two Novel Clusters in Calcium Oxalate Stones With Urinary Tract Infection Using 16S rDNA Sequencing.

Authors:  Chen Shen; Qianhui Zhu; Fan Dong; Wei Wang; Bo Fan; Kexin Li; Jun Chen; Songnian Hu; Zilong He; Xiancheng Li
Journal:  Front Cell Infect Microbiol       Date:  2021-11-17       Impact factor: 5.293

6.  Short Chain Fatty Acids Prevent Glyoxylate-Induced Calcium Oxalate Stones by GPR43-Dependent Immunomodulatory Mechanism.

Authors:  Xi Jin; Zhongyu Jian; Xiaoting Chen; Yucheng Ma; Hongwen Ma; Yu Liu; Lina Gong; Liyuan Xiang; Shiyu Zhu; Xiaoling Shu; Shiqian Qi; Hong Li; Kunjie Wang
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

7.  Identification of Resolvin D1 and Protectin D1 as Potential Therapeutic Agents for Treating Kidney Stones.

Authors:  Bohan Wang; Jingchao Wei; Qi Huangfu; Fei Gao; Lanxin Qin; Jiao Zhong; Jiaming Wen; Zhangqun Ye; Xiaoqi Yang; Haoran Liu
Journal:  Oxid Med Cell Longev       Date:  2022-02-24       Impact factor: 7.310

8.  Low-Dose Interleukin-2 Altered Gut Microbiota and Ameliorated Collagen-Induced Arthritis.

Authors:  Na Li; Xuefei Li; Rui Su; Ruihe Wu; Hong-Qing Niu; Jing Luo; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  J Inflamm Res       Date:  2022-02-25

9.  Gut microbiota and the prevalence and incidence of renal stones.

Authors:  Han-Na Kim; Jae Heon Kim; Yoosoo Chang; Dongmin Yang; Kwan Joong Joo; Young-Sam Cho; Heung Jae Park; Hyung-Lae Kim; Seungho Ryu
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

Review 10.  The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease.

Authors:  Yinghui Huang; Wang Xin; Jiachuan Xiong; Mengying Yao; Bo Zhang; Jinghong Zhao
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.